Literature DB >> 9765459

The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth.

C C Smith1, T Peng, M Kulka, L Aurelian.   

Abstract

The large subunit of herpes simplex virus (HSV) ribonucleotide reductase (RR), RR1, contains a unique amino-terminal domain which has serine/threonine protein kinase (PK) activity. To examine the role of the PK activity in virus replication, we studied an HSV type 2 (HSV-2) mutant with a deletion in the RR1 PK domain (ICP10DeltaPK). ICP10DeltaPK expressed a 95-kDa RR1 protein (p95) which was PK negative but retained the ability to complex with the small RR subunit, RR2. Its RR activity was similar to that of HSV-2. In dividing cells, onset of virus growth was delayed, with replication initiating at 10 to 15 h postinfection, depending on the multiplicity of infection. In addition to the delayed growth onset, virus replication was significantly impaired (1,000-fold lower titers) in nondividing cells, and plaque-forming ability was severely compromised. The RR1 protein expressed by a revertant virus [HSV-2(R)] was structurally and functionally similar to the wild-type protein, and the virus had wild-type growth and plaque-forming properties. The growth of the ICP10DeltaPK virus and its plaque-forming potential were restored to wild-type levels in cells that constitutively express ICP10. Immediate-early (IE) genes for ICP4, ICP27, and ICP22 were not expressed in Vero cells infected with ICP10DeltaPK early in infection or in the presence of cycloheximide, and the levels of ICP0 and p95 were significantly (three- to sevenfold) lower than those in HSV-2- or HSV-2(R)-infected cells. IE gene expression was similar to that of the wild-type virus in cells that constitutively express ICP10. The data indicate that ICP10 PK is required for early expression of the viral regulatory IE genes and, consequently, for timely initiation of the protein cascade and HSV-2 growth in cultured cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765459      PMCID: PMC110331     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  77 in total

1.  Identification of immediate-early-type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2.

Authors:  J P Wymer; T D Chung; Y N Chang; G S Hayward; L Aurelian
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

2.  Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression.

Authors:  C I Ace; T A McKee; J M Ryan; J M Cameron; C M Preston
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

3.  Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target.

Authors:  J M Cameron; I McDougall; H S Marsden; V G Preston; D M Ryan; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

4.  Herpes simplex virus genes involved in latency in vitro.

Authors:  J Russell; N D Stow; E C Stow; C M Preston
Journal:  J Gen Virol       Date:  1987-12       Impact factor: 3.891

5.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

6.  Activation of immediate-early, early, and late promoters by temperature-sensitive and wild-type forms of herpes simplex virus type 1 protein ICP4.

Authors:  N A DeLuca; P A Schaffer
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

7.  Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture.

Authors:  W R Sacks; P A Schaffer
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

8.  The herpes simplex virus type 1 ribonucleotide reductase is a tight complex of the type alpha 2 beta 2 composed of 40K and 140K proteins, of which the latter shows multiple forms due to proteolysis.

Authors:  R Ingemarson; H Lankinen
Journal:  Virology       Date:  1987-02       Impact factor: 3.616

9.  Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient.

Authors:  A M McCarthy; L McMahan; P A Schaffer
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

10.  Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  Virology       Date:  1988-09       Impact factor: 3.616

View more
  22 in total

1.  Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.

Authors:  S Q Wales; C C Smith; M Wachsman; G Calton; L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro.

Authors:  M R Chen; S J Chang; H Huang; J Y Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  The growth compromised HSV-2 mutant DeltaRR prevents kainic acid-induced apoptosis and loss of function in organotypic hippocampal cultures.

Authors:  Michael D Gober; Jennifer M Laing; Scott M Thompson; Laure Aurelian
Journal:  Brain Res       Date:  2006-10-03       Impact factor: 3.252

4.  The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an in vivo model of neurodegeneration associated with glutamate excitotoxicity.

Authors:  Erin K Golembewski; Samantha Q Wales; Laure Aurelian; Paul J Yarowsky
Journal:  Exp Neurol       Date:  2006-10-16       Impact factor: 5.330

5.  A single viral gene determines lethal cross-species neurovirulence of baboon herpesvirus HVP2.

Authors:  Darla Black; Kazutaka Ohsawa; Shaun Tyler; Lara Maxwell; R Eberle
Journal:  Virology       Date:  2014-01-29       Impact factor: 3.616

6.  Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice.

Authors:  Jennifer M Laing; Michael D Gober; Erin K Golembewski; Scott M Thompson; Kymberly A Gyure; Paul J Yarowsky; Laure Aurelian
Journal:  Mol Ther       Date:  2006-02-24       Impact factor: 11.454

7.  A short polypeptide from the herpes simplex virus type 2 ICP10 gene can induce antigen aggregation and autophagosomal degradation for enhanced immune presentation.

Authors:  Xinping Fu; Lihua Tao; Xiaoliu Zhang
Journal:  Hum Gene Ther       Date:  2010-12       Impact factor: 5.695

8.  The herpes simplex virus type 2 gene ICP10PK protects from apoptosis caused by nerve growth factor deprivation through inhibition of caspase-3 activation and XIAP up-regulation.

Authors:  Samantha Q Wales; Baiquan Li; Jennifer M Laing; Laure Aurelian
Journal:  J Neurochem       Date:  2007-10       Impact factor: 5.372

Review 9.  Herpes simplex virus type 2 vaccines: new ground for optimism?

Authors:  L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

10.  Multi-targeted neuroprotection by the HSV-2 gene ICP10PK includes robust bystander activity through PI3-K/Akt and/or MEK/ERK-dependent neuronal release of vascular endothelial growth factor and fractalkine.

Authors:  Jennifer M Laing; Cynthia C Smith; Laure Aurelian
Journal:  J Neurochem       Date:  2009-11-05       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.